Kardigan (KARD)
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfoli...
- Open
- 20.470
- High
- 21.755
- Low
- 20.460
- Prev. Close
- 20.260
- Volume
- 159.58K
- Turnover
- 3.35M
- Avg Price
- 21.023
- Bid/Ask Ratio
- --
- Amplitude
- 6.39%
- 52wk High
- 27.000
- Volume Ratio
- 0.77
- Turnover Ratio
- 0.31%
Kardigan Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$43.50106.95%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- MorningStar · Aug 14 at 03:30 AM
Dow Jones Top Energy Headlines at 4 AM ET: BP, XRG Partner on Venezuela Offshore Gas Development | Rick ...
- TradingView · Aug 11 at 06:21 AM
Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary
- Earnings Watch · Aug 11 at 06:07 AM
Kardigan | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 11 at 06:01 AM
Kardigan Q2 FY26 net loss widens to $116.24 million; R&D expenses rise to $56.37 million
- Market Beat · Aug 11 at 05:44 AM
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Rating of "Moderate Buy" from Analysts
- Market Beat · Jul 21 at 12:20 AM
Kardigan, Inc.'s (NASDAQ:KARD) Quiet Period To End on July 28th
